Cantor Fitzgerald Initiates Coverage On Lucid Diagnostics with Overweight Rating, Announces Price Target of $21
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Overweight rating and announces Price Target of $21.